SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported ...

Considered to be one of the greatest revolutions in cancer treatment, immunotherapy enhances the immune system's ability to ...

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas ...

Xilio anticipates nominating a development candidate for its PSMA program in the ATACR format in the third quarter of 2025 ...

WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year – – ...

First patient dosed in study investigating roginolisib + dostarlimab +/- docetaxel in patients with NSCLC who have progressed on prior immunotherapy/chemo Study will evaluate ...

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments, including ...

PAD symptoms often manifest in the feet due to fatty deposits like cholesterol building up in the arteries. The British Heart ...

Glaucoma silently steals vision before symptoms appear. Learn the subtle warning signs, who faces highest risk, and the ...

Actinium Pharmaceuticals, Inc. (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that the first patient was enrolled on the trial studying Iomab-ACT ...

The transition from preclinical development to clinical trials is a critical, with approximately 89% of drugs failing. Nearly half of these failures stem from unexpected and unmanageable human ...

Researchers in Japan found that estrogen produced within the brain, called neuroestrogen, suppresses appetite and reduces ...